NEW YORK (GenomeWeb News) – Noninvasive prenatal test developer Natera has completed a $54.6 million financing round to support its expansion and the rollout of its sequencing-based fetal aneuploidy test called Panorama.

Two new investors, OrbiMed Advisors and Harmony Partners, and other new undisclosed investors joined the company's existing investors, Claremont Creek Ventures, Lightspeed Venture Partners, Founders Fund, and Sequoia Capital.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A lack of funding may lead more than two dozen research facilities in Australia to shut down in three months.

Researchers report that paternally inherited genes are more likely to be expressed in mice.

In Genome Research this week: multiplex genotyping of germline and somatic short tandem repeats, graph-based regularization, and more.

In PNAS this week: Akt3 amplification in glioma progression, Tibetan Plateau frog genome, and more.